Curcumin in various cancers

BioFactors

Volumn 39, Issue 1, 2013, Pages 56-68

  Shehzad, Adeeb ^a   Lee, Jaetae ^b   Lee, Young Sup ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

Author keywords

Cancer; Chemoprevention; Curcumin; Multiple targets; Therapeutic agent

Indexed keywords

ALKALINE PHOSPHATASE; CURCUMIN; DEMETHOXYCURCUMIN; DOCETAXEL; LACTATE DEHYDROGENASE; PLACEBO;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BLADDER CARCINOGENESIS; BONE CANCER; BRAIN TUMOR; BREAST ADENOCARCINOMA; BREAST CANCER; BRONCHUS CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHEST TIGHTNESS; COLON ADENOCARCINOMA; COLON CANCER; COLORECTAL CANCER; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG ERUPTION; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GASTROINTESTINAL SYMPTOM; GENITAL SYSTEM; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CANCER; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; STOMACH CANCER; THYMUS CANCER; URINARY TRACT CANCER; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CURCUMIN; HUMANS; MEDICINE, TRADITIONAL; MOLECULAR TARGETED THERAPY; NEOPLASMS;

ANIMALIA; CURCUMA LONGA;

EID: 84874114084     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1068     Document Type: Review

References (110)

1. Morgan, D. O. ( 2007) The Cell Cycle: Principles of Control, New Science Press, Ltd.: London, UK.
2. Salk, J. J., Fox, E. J., and Loeb, L. A. ( 2010) Mutational heterogeneity in human cancers: origin and consequences. Annu. Rev. Pathol. 5, 51-75.
3. Siegel, R., Naishadham, D., and Jemal, A. ( 2012) Cancer statistic. CA Cancer. J. Clin. 62, 10-29.
4. Shehzad, A., Ha, T., Subhan, F., and Lee, Y. S. ( 2011) New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur. J. Nutr. 50, 151-61.
5. Shehzad, A., Khan, S., and Lee, Y. S. ( 2012) Curcumin molecular targets in obesity and obesity-related cancers. Future Oncol. 8, 179-190.
6. Shehzad, A., Wahid, F., and Lee, Y. S. ( 2010). Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm. (Weinheim). 343, 489-499.
7. Bandyopadhyay, U., Das, D., and Banerjee, R. K. ( 1999) Reactive oxygen species: oxidative damage and pathogenesis. Curr. Sci. 77, 658-666.
8. Jovanovic, S. V., Steenken, S., Boone, C. W., and Simic, M. G. ( 1999) H-atom transfer is a preferred antioxidant mechanism of curcumin. J. Am. Chem. Soc. 121, 9677-9681.
9. Wang, Y. J., Pan, M. H., Cheng, A. L., Lin, L. I., Ho, Y. S., et al. ( 1997) Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal. 15, 1867-1876.
10. Somparn, P., Phisalaphong, C., Nakornchai, S., Unchern, S., and Morales, N. P. ( 2007) Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol. Pharm. Bull. 30, 74-78.
11. Anand, P., Thomas, S. G., Kunnumakkara, A. B. Sundaram, C., Harikumar, K. B., et al. ( 2008) Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem. Pharmacol. 76, 1590-1611.
12. Shehzad, A., Khan, S., Shehzad, O., and Lee, Y. S. ( 2010) Curcumin therapeutic promises and bioavailability in colorectal cancer. Drugs Today. 46, 523-532.
13. Shehzad, A., and Lee, Y. S. ( 2010) Curcumin: multiple molecular targets mediate multiple pharmacological actions: a review. Drugs Future. 35, 113-119.
14. Lao, C. D., Ruffin, M. T., Normolle, D., Heath, D. D., Murray, S. I., et al. ( 2006) Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med. 6, 10.
15. Gupta, S. C., Prasad, S., Kim, J. H., Patchva, S., Webb, L. J., et al. ( 2011) Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep. 28, 1937-1955.
16. Selvam, C., Jachak, S. M., Thilagavathi, R., and Chakraborti, A. K. ( 2005) Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg. Med. Chem. Lett. 15, 1793-1797.
17. Padhye, S., Banerjee, S., Chavan, D., Pandye, S., Swamy, K. V., et al. ( 2009) Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res. 26, 2438-2445.
18. Goel, A., and Aggarwal, B. B. ( 2010) Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr. Cancer. 62, 919-930.
19. Yu, S., Shen, G., Khor, T. O., Kim, J. H., and Kong, A. N. ( 2008) Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol. Cancer. Ther. 7, 2609-2620.
20. Collett, G. P., and Campbell, F. C. ( 2004) Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25, 2183-2189.
21. Camacho-Barquero, L., Villegas, I., Sánchez-Calvo, J. M., Talero, E., Sánchez-Fidalgo, S., et al. ( 2007) Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int. Immunopharmacol. 7, 333-342.
22. Aggarwal, B. B., Vijayalekshmi, R. V., and Sung, B. ( 2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer. Res. 15, 425-430.
23. Park, C. H., Hahm, E. R., Park, S., Kim, H. K., and Yang, C. H. ( 2005) The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett. 579, 2965-2971.
24. Sa, G., and Das, T. ( 2008) Anti cancer effects of curcumin: cycle of life and death. Cell. Div. 3, 14.
25. Hartojo, W., Silvers, A. L., Thomas, D. G., Seder, C. W., Lin, L., et al. ( 2010) Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl. Oncol. 3, 99-108.
26. Bower, M. R., Aiyer, H. S., Li, Y., and Martin, R. C. ( 2010) Chemoprotective effects of curcumin in esophageal epithelial cells exposed to bile acids. World. J. Gastroenterol. 16, 4152-4158.
27. O'Sullivan-Coyne, G., O'Sullivan, G. C., O'Donovan, T. R., Piwocka, K., and McKenna, S. L. ( 2009) Curcumin induces apoptosis-independent death in oesophageal cancer cells. Br. J. Cancer. 101, 1585-1595.
28. Subramaniam, D., Ponnurangam, S., Ramamoorthy, P., Standing, D., Battafarano, R. J., et al. ( 2012) Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One 7, e30590.
29. Rawat, N., Alhamdani, A., McAdam, E., Cronin, J., Eltahir, Z., et al. ( 2012) Curcumin abrogates bile-induced NF-κB activity and DNA damage in vitro and suppresses NF-κB activity whilst promoting apoptosis in vivo, suggesting chemopreventative potential in Barrett's oesophagus. Clin. Transl. Oncol. 14, 302-311.
30. Ushida, J., Sugie, S., Kawabata, K., Pham, Q. V., Tanaka, T., et al. ( 2000) Chemopreventive effect of curcumin on Nnitrosomethylbenzylamine- induced esophageal carcinogenesis in rats. Jpn. J. Cancer. Res. 91, 893-898.
31. Cai, X. Z., Wang, J., Li, X. D., Wang, G. L., Liu, F. N., et al. ( 2009) Curcumin suppresses proliferation and invasion in human gastric cancer cells by downregulation of PAK1 activity and cyclin D1 expression. Cancer Biol. Ther. 8, 1360-1368.
32. Sintara, K., Thong-Ngam, D., Patumraj, S., and Klaikeaw, N. ( 2012) Curcumin attenuates gastric cancer induced by N-methyl-N-nitrosourea and saturated sodium chloride in rats. J. Biomed. Biotechnol. 2012, 915380.
33. Koo, J. Y., Kim, H. J., Jung, K. O., and Park, K. Y. ( 2004) Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J. Med. Food. 7, 117-121.
34. Shishodia, S., Chaturvedi, M. M., and Aggarwal, B. B. ( 2007) Role of curcumin in cancer therapy. Curr. Probl. Cancer. 31, 243-305.
35. Mahmoud, N. N., Carothers, A. M., Grunberger, D., Bilinski, R. T., Churchill, M. R., et al. ( 2000) Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 21, 921-927.
36. Perkins, S., Verschoyle, R. D., Hill, K., Parveen, I., Threadgill, M. D., et al. ( 2002) Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+mouse, a model of familial adenomatous polyposis. Cancer Epidemiol. Biomarkers. Prev. 11, 535-540.
37. Murphy, E. A., Davis, J. M., McClellan, J. L., and Gordon, B. T. ( 2011) Carmichael MD. Curcumin's effect on intestinal inflammation and tumorigenesis in the ApcMin/+ mouse. J. Interferon. Cytokine. Res. 31, 219-226.
38. Johnson, J. J., and Mukhtar, H. ( 2007) Curcumin for chemoprevention of colon cancer. Cancer Lett. 255, 170-181.
39. Sharma, R. A., McLelland, H. R., Hill, K. A., Ireson, C. R., Euden, S. A., et al. ( 2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer. Res. 7, 1894-1900.
40. Sharma, R. A., Euden, S. A., Platton, S. L., Cooke, D. N., Shafayat, A., et al. ( 2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer. Res. 10, 6847-6854.
41. Garcea, G., Berry, D. P., Jones, D. J., Singh, R., Dennison, A. R., et al. ( 2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomarkers Prev. 14, 120-125.
42. He, Z. Y., Shi, C. B., Wen, H., Li, F. L., Wang, B. L., et al. ( 2011) Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 29, 208-213.
43. Ohashi, Y., Tsuchiya, Y., Koizumi, K., Sakurai, H., and Saiki, Y. ( 2003) Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology. 65, 250-258.
44. Kang, J., Chen, J., Shi, Y., Jia, J., and Zhang, Y. ( 2005) Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem. Pharmacol. 69, 1205-1213.
45. Cao, J., Jia, L., Zhou, H. M., Liu, Y., and Zhong, L. F. ( 2006) Mitochondrial and nuclear DNA damage induced by curcumin in human hepatoma G2 cells. Toxicol. Sci. 91, 476-483.
46. Darvesh, A. S., Aggarwal, B. B., and Bishayee, A. ( 2012) Curcumin and liver cancer: a review. Curr. Pharm. Biotechnol. 13, 218-228.
47. Huang, A. C., Lin, S. Y., Su, C. C., Lin, S. S., Ho, C. C., et al. ( 2008) Effects of curcumin on N-bis(2-hydroxypropyl) nitrosamine (DHPN)-induced lung and liver tumorigenesis in BALB/c mice in vivo. In Vivo 22, 781-786.
48. Lin, L. I., Ke, Y. F., Ko, Y. C., and Lin, J. K. ( 1998) Curcumin inhibits SKHep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology 55, 349-353.
49. Li, L., Aggarwal, B. B., Shishodia, S., Abbruzzese, J., and Kurzrock, R. ( 2004) Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101, 2351-2362.
50. Wang, Z., Zhang, Y., Banerjee, S., Li, Y., and Sarkar, F. H. ( 2006) Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106, 2503-2513.
51. Lev-Ari, S., Vexler, A., Starr, A., Ashkenazy-Voghera, M., Greif, J., et al. ( 2007) Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest. 25, 411-418.
52. Sahu, R. P., Batra, S., and Srivastava, S. K. ( 2009) Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br. J. Cancer 100, 1425-1433.
53. Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B., and Aggarwal, B. B. ( 2008) Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 267, 133-164.
54. Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., et al. ( 2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14, 4491-4499.
55. Tian, B., Wang, Z., Zhao, Y., Wang, D., Li, Y., et al. ( 2008) Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett. 264, 299-308.
56. Chadalapaka, G., Jutooru, I., Chintharlapalli, S., Papineni, S., Smith, R., et al. ( 2008) Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res. 68, 5345-5354.
57. Saini, S., Arora, S., Majid, S., Shahryari, V., Chen, Y., et al. ( 2011) Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev. Res (Phila). 4, 1698-1709.
58. Watanabe, F. T., Chade, D. C., Reis, S. T., Piantino, C, Dall' Oglio, M. F., et al. ( 2011) Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model. Clinics (Sao Paulo). 66, 2121-2124.
59. Woo, J. H., Kim, Y. H., Choi, Y. J., Kim, D. G., Lee, K. S., et al. ( 2003) Molecular mechanisms of curcumininduced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 24, 1199-1208.
60. Jung, E. M., Lim, J. H., Lee, T. J., Park, J. W., Choi, K. S., et al. ( 2005) Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 26, 1905-1913.
61. Frank, N., Knauft, J., Amelung, F., Nair, J., Wesch, H., et al. ( 2003) No prevention of liver and kidney tumors in Long-Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of metastases. Mutat. Res. 523-524, 127-135.
62. Aggarwal, B. B. ( 2008) Prostate cancer and curcumin. Cancer Biol. Thera. 7, 1436-1440.
63. Dorai, T., Cao, Y. C., Dorai, B., Buttyan, R., and Katz, A. E. ( 2001) Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate. 47, 293-303.
64. Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., and Aggarwal, B. B. ( 2001) Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 20, 7597-7609.
65. Cimino, S., Sortino, G., Favilla, V., Castelli, T., Madonia, M., et al. ( 2012) Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid. Med. Cell. Longev. 2012, 632959.
66. Sundram V, Chauhan SC, Ebeling M, and Jaggi M. ( 2012) Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One. 7, e35368.
67. Capodice, J. L., Gorroochurn, P., Cammack, A. S., Eric, G., McKiernan, J. M., et al. ( 2009) Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J. Soc. Integr. Oncol. 7, 43-51.
68. Divya, C. S., and Pillai, M. R. ( 2006) Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol. Carcinog. 45, 320-332.
69. Singh, M., and Singh, N. ( 2009) Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol. Cell. Biochem. 325, 107-119.
70. Maher, D. M., Bell, M. C., O'Donnell, E. A., Gupta, B. K., Jaggi, M., et al. ( 2011) Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol. Carcinog. 50, 47-57.
71. Lin, Y. G., Kunnumakkara, A. B., Nair, A., Merritt, W. M., Han, L. Y., et al. ( 2007) Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin. Cancer Res. 13, 3423-3430.
72. Watson, J. L., Greenshields, A., Hill, R., Hilchie, A., Lee, P. W., et al. ( 2010) Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol. Carcinog. 49, 13-24.
73. Mukherjee, N., Chakraborty, S., Ghosh, U., Bhattacharyya, N. P., Bhattacharya, R. K., et al. ( 2007) Curcumin-induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Mol. Cell. Biochem. 297, 31-39.
74. Ghosh, A. K., Kay, N. E., Secreto, C. R., and Shanafelt, T. D. ( 2009) Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin. Cancer Res. 15, 1250-1258.
75. Yang, C. W., Chang, C. L., Lee, H. C., Chi, C. W., Pan, J. P., et al. ( 2012) Curcumin induces the apoptosis of human monocytic leukemia THP-1 cells via the activation of JNK/ERK pathways. BMC Complement. Altern. Med. 12, 22.
76. Gao, S. M., Yang, J. J., Chen, C. Q., Chen, J. J., Ye, L. P., et al. ( 2012) Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. J. Exp. Clin. Cancer Res. 31, 27.
77. Hussain, A. R., Ahmed, M., Al-Jomah, N. A., Khan, A. S., Manogaran, P., et al. ( 2008) Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol. Cancer Ther. 7, 3318-3329.
78. Li, Z. X., Ouyang, K. Q., Jiang, X., Wang, D., and Hu, Y. ( 2009) Curcumin induces apoptosis and inhibits growth of human Burkitt's lymphoma in xenograft mouse model. Mol. Cells 27, 283-289.
79. Zhang, C., Li, B., Zhang, X., Hazarika, P., Aggarwal, B. B., et al. ( 2010) Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. J. Invest. Dermatol. 130, 2110-2119.
80. Bharti, A. C., Donato, N., and Aggarwal, B. B. ( 2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 171, 3863-3871.
81. Bharti, A. C., Donato, N., Singh, S., and Aggarwal BB. ( 2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101, 1053-1062.
82. Sung, B., Kunnumakkara, A. B., Sethi, G., Anand, P., Guha, S., et al. ( 2009) Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol. Cancer Ther. 8, 959-970.
83. Vadhan, R. S., Weber, D., Giralt, S., Alexanian, R., Thomas, S., et al. ( 2007) Curcumin downregulates NF-κB and related genes in patients with multiple myeloma: results of a phase I/II study. Blood (ASH Annual Meeting Abstracts) 110, 1177a.
84. Golombick, T., Diamond, T. H., Manoharan, A., and Ramakrishna, R. ( 2012) Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am. J. Hematol. 87, 455-460.
85. Golombick, T., Diamond, T. H., Badmaev, V., Manoharan, A., and Ramakrishna, R. ( 2009) The potential role of curcumin in patients with monoclonal gammopathy of undefined significance--its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin. Cancer Res. 15, 5917-5922.
86. Yang, C. L., Ma, Y. G., Xue, Y. X., Liu, Y. Y., Xie, H., et al. ( 2012) Curcumin induces small cell lung cancer NCI-H446 cell apoptosis via the reactive oxygen species-mediated mitochondrial pathway and not the cell death receptor pathway. DNA Cell Biol. 31, 139-150.
87. Chen, H. W., Lee, J. Y., Huang, J. Y., Wang, C. C., Chen, W. J., et al. ( 2008) Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res. 68, 7428-7438.
88. Tung, Y. T., Chen, H. L., Lai, C. W., Shen, C. J., Lai, Y. W., et al. ( 2011) Curcumin reduces pulmonary tumorigenesis in vascular endothelial growth factor (VEGF)-overexpressing transgenic mice. Mol. Nutr. Food. Res. 55, 1036-1043.
89. Polasa, K., Raghuram, T. C., Krishna, T. P., and Krishnaswamy, K. ( 1992) Effect of turmeric on urinary mutagens in smokers. Mutagenesis 7, 107-109.
90. Jurrmann, N., Brigelius-Flohé, R., and Böl, G. F. ( 2005) Curcumin blocks interleukin-1 (IL-1) signaling by inhibiting the recruitment of the IL-1 receptor-associated kinase IRAK in murine thymoma EL-4 cells. J. Nutr. 135, 1859-1864.
91. Bhattacharyya, S., Mandal, D., Sen, G. S., Pal, S., Banerjee, S., et al. ( 2007) Tumor-induced oxidative stress perturbs nuclear factorkappaB activity-augmenting tumor necrosis factor-alpha mediated T-cell death: protection by curcumin. Cancer Res. 67, 362-370.
92. Chang, Y. F., Chuang, H. Y., Hsu, C. H., Liu, R. S., Gambhir, S. S., et al. ( 2012) Immunomodulation of curcumin on adoptive therapy with T cell functional imaging in mice. Cancer Prev. Res (Phila). 5, 444-452.
93. Sun, S. H., Huang, H. C., Huang, C., and Lin, J. K. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. Eur. J. Pharmacol. 690, 22-30.
94. Zhang, H. G., Kim, H., Liu, C., Yu, S., Wang, J., et al. ( 2007) Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. Biochim. Biophys. Acta 1773, 1116-1123.
95. Bayet-Robert, M., Kwiatkowski, F., Leheurteur, M., Gachon, F., Planchat, E., et al. ( 2010) Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol. Ther. 9, 8-14.
96. Liu, E., Wu, J., Cao, W., Zhang, J., Liu, W., et al. ( 2007) Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J. Neurooncol. 85, 263-270.
97. Mythri, R. B., and Bharath, M. M. ( 2012) Curcumin: a potential neuroprotective agent in Parkinson's disease. Curr. Pharm. Des. 18, 91-99.
98. Karmakar, S., Banik, N. L., Patel, S. J., and Ray, S. K. ( 2006) Curcumin activated both receptor-mediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells. Neurosci. Lett. 407, 53-58.
99. Zanotto-Filho, A., Braganhol, E., Edelweiss, M. I., Behr, G. A., Zanin, R., et al. ( 2012) The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. J. Nutr. Biochem. 23, 591-601.
100. Zhuang, W., Long, L., Zheng, B., Ji, W., Yang, N., et al. ( 2012) Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy. Cancer Sci. 103, 684-690.
101. Lee, D. S., Lee, M. K., and Kim, J. H. ( 2009) Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells. Anticancer Res. 29, 5039-5044.
102. Guimarães, M. R., Coimbra, L. S., de Aquino, S. G., Spolidorio, L. C., Kirkwood, K. L., et al. ( 2011) Potent anti-inflammatory effects of systemically administered curcumin modulate periodontal disease in vivo. J. Periodontal. Res. 46, 269-279.
103. von Metzler, I., Krebbel, H., Kuckelkorn, U., Heider, U., Jakob, C., et al. ( 2009) Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase. J. Cancer Res. Clin. Oncol. 135, 173-179.
104. Kumar Mitra, A., Mitra, and Krishna, M. ( 2004) In vivo modulation of signaling factors involved in cell survival. J. Radiat. Res. 45, 491-495.
105. Anand, P., Kunnumakkara, A. B., Newman, R. A., and Aggarwal, B. B. ( 2007) Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807-818.
106. Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., et al. ( 1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64, 353-356.
107. Gota, V. S., Maru, G. B., Soni, T. G., Gandhi, T. R., Kochar, N., et al. ( 2010) Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food. Chem. 58, 2095-2099.
108. Cuomo, J., Appendino, G., Dern, A. S., Schneider, E., McKinnon, T. P., et al. 2011. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J. Nat. Prod. 74, 664-669.
109. Sasaki, H., Sunagawa, Y., Takahashi, K., Imaizumi, A., Fukuda, H., et al. ( 2011) Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 34, 660-665.
110. Antony, B., Merina, B., Iyer, V. S., Judy, N., Lennertz, K., et al. ( 2008) A pilot cross-over study to evaluate human oral bioavailability of bcm-95cg (biocurcumax), a novel bioenhanced preparation of curcumin. Indian. J. Pharm Sci. 70, 445-449.